Neumora Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

NMRA$0.47-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

(in thousands)

	Year Ended December 31,
	2024	2023	2022
Operating activities:
Net loss	$(243,787)	$(235,925)	$(130,904)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development	—	63,904	13,000
Stock-based compensation	39,990	17,240	8,298
Non-cash operating lease expense	3,290	3,355	2,103
Depreciation and amortization	631	668	594
Net accretion of investments in marketable securities	(5,719)	(3,741)	(708)
Change in fair value of convertible preferred stock warrants	—	—	(559)
Other noncash expenses	23	120	228
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	15,905	(11,401)	(3,628)
Other assets	—	—	1,373
Accounts payable	2,873	(581)	(1,246)
Accrued liabilities	7,236	6,486	(1,621)
Operating lease liabilities	(3,378)	(3,403)	(1,826)
Net cash used in operating activities	(182,936)	(163,278)	(114,896)
Investing activities:
Purchases of marketable securities	(312,223)	(109,072)	(226,369)
Cash paid for acquisition of assets, including upon achievement of milestones	(775)	(4,590)	(13,000)
Proceeds from maturities of marketable securities	242,441	178,166	71,867
Purchases of property and equipment	—	(117)	(511)
Net cash provided by (used in) investing activities	(70,557)	64,387	(168,013)
Financing activities:
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions	—	232,565	—
Proceeds from issuance of common stock in at-the-market transactions, net of commissions and offering costs	13,694	—	—
Proceeds from issuance of convertible preferred stock, net of issuance costs	—	—	112,216
Proceeds from exercise of stock options	7,482	2,856	2,658
Proceeds from employee stock purchase plan purchases	427	—	—
Proceeds from exercise of warrants	—	—	1,613
Proceeds from issuance of common stock	—	810	—
Repurchase of unvested early exercised shares	—	(491)	—
Payments for deferred offering costs	—	(3,804)	(744)
Net cash provided by financing activities	21,603	231,936	115,743
Net change in cash and cash equivalents and restricted cash	(231,890)	133,045	(167,166)
Cash and cash equivalents and restricted cash at beginning of year	375,251	242,206	409,372
Cash and cash equivalents and restricted cash at end of period	$143,361	$375,251	$242,206
Components of cash and restricted cash:
Cash and cash equivalents	$142,148	$374,038	$240,943
Restricted cash	1,213	1,213	1,263
Total cash and cash equivalents and restricted cash	$143,361	$375,251	$242,206
Supplemental disclosure of cash flow information:
Operating lease liabilities arising from obtaining right-of-use assets	$—	$192	$8,865
Cash paid for income taxes	$473	$—	$—
Supplemental disclosure of noncash investing and financing activities:
Acquisition of assets included in accounts payable and accrued liabilities	$—	$775	$—
Purchase of property and equipment included in accounts payable	$—	$44	$505
Conversion of preferred stock into common stock upon completion of initial public offering	$—	$843,687	$—
Issuance of common stock upon achievement of milestone related to acquisition of assets	$—	$58,539	$—
Offering costs related to initial public offering included in accounts payable and accrued liabilities	$—	$—	$340

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.